Assessment Of Fc-Mediated Functional Activity For The Development Of Complex Biologics And Bioconjugates

Access the on-demand webinar to hear expert insights from Dr. Erika Kovacs, Sr. Director of Bioassay, and Dr. Rosa Gonzalez-Serrano, Sr. Manager of Bioassay, as they discuss strategies for phase-appropriate assessment of Fc-mediated functional activity and share new advancements for evaluating complex biologic modalities.

Many cancer therapeutics rely on mechanisms such as ADCC, ADCP, and CDC to achieve cytotoxicity against target cells—making accurate functional assessment essential before advancing candidates into the clinic. Just as critical is demonstrating the absence of unwanted effector functions to ensure safety.

In this session, our experts explore key considerations in developing effective Fc-mediated functional assays, highlighting the advantages and limitations of various assay formats. They also provide guidance on selecting optimal target cell lines, effector cells, and controls, and share case studies illustrating how data trending supports assay reliability.

Finally, they present emerging approaches, including real-time spheroid cytotoxicity assays, that offer deeper insights into mechanism of action and support lead candidate selection.

Watch now to gain a comprehensive overview of how to evaluate Fc-mediated functions—and why doing so is vital to the success of biologic therapies.